Beatrijs H. Wokke
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis.
Journal: Neurology and therapy
Published: March 05, 2026
Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: February 16, 2026
Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.
Journal: Journal of neurology
Published: December 09, 2025
Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.
Journal: Journal of neurology
Published: November 22, 2025
Genetic and environmental mediators of multiple sclerosis susceptibility but not early severity run in families.
Journal: Multiple sclerosis and related disorders
Published: September 12, 2025
Brain Atrophy Associated With Risk Variant rs10191329 Extends Beyond Multiple Sclerosis.
Journal: Annals of neurology
Published: September 12, 2025
Perturbances in Both Circulating B and CD4+ T Cells Discriminate Multiple Sclerosis from Other Central Nervous System Autoimmune Diseases.
Journal: European journal of immunology
Published: May 23, 2025
Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis.
Journal: Therapeutic advances in neurological disorders
Published: April 06, 2025
Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors.
Journal: Scientific reports
Published: February 04, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 31, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 04, 2024
Last Updated: 09/26/2026